The Amicus benchmark

There is at least one benchmark for studying a new Fabry's treatment. Amicus Therapeutics Inc. and partner GlaxoSmithKline plc are conducting two Phase III trials of Amigal migalastat, a small molecule that enhances alpha galactosidase A activity.